Premium
Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study
Author(s) -
Toyokura Yasuo,
Mizuno Yoshikuni,
Kase Masao,
Sobue Itsuro,
Kuroiwa Yoshigoro,
Narabayashi Hirotaro,
Uono Masanori,
Nakanishi Takao,
Kameyama Masakuni,
Ito Hitoshi,
Shimada Yasuo,
Iwata Makoto
Publication year - 1985
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1985.tb00858.x
Subject(s) - bromocriptine , parkinsonism , double blind , medicine , psychology , psychiatry , alternative medicine , pathology , disease , prolactin , hormone , placebo
– The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement ( P < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.